(Reuters) – Acceleron Pharma Inc (O:) said on Monday its investigational treatment for pulmonary arterial hypertension met the main goal in a mid-stage trial, sending its shares surging 53%.
The treatment, sotatercept, showed significant reduction in pulmonary vascular resistance versus placebo at week 24.
Pulmonary arterial hypertension, or PAH, occurs when arteries in the lungs constrict, forcing the heart to work harder and potentially leading to heart failure. Its symptoms include shortness of breath and fatigue.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.